OBJECTIVE: To examine the relationship between cholesterol and other lipids, APOE genotype, and risk of Alzheimer disease (AD) in a population-based study of elderly Yoruba living in Ibadan, Nigeria. METHODS: Blood samples and clinical data were collected from Yoruba study participants aged 70 years and older (N = 1,075) as part of the Indianapolis-Ibadan Dementia Project, a longitudinal epidemiologic study of AD. Cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride levels were measured in fasting blood samples. DNA was extracted and APOE was genotyped. Diagnoses of AD were made by consensus using National Institute of Neurologic Disorders/Stroke-Alzheimer's Disease and Related Disorders Association criteria. RESULTS: Logistic regression models showed interaction after adjusting for age and gender between APOE-epsilon4 genotype and biomarkers in the risk of AD cholesterol*genotype (p = 0.022), LDL*genotype (p= 0.018), and triglyceride*genotype (p = 0.036). Increasing levels of cholesterol and LDL were associated with increased risk of AD in individuals without the APOE-epsilon4 allele, but not in those with APOE-epsilon4. There was no significant association between levels of triglycerides and AD risk in those without APOE-epsilon4. CONCLUSIONS: There was a significant interaction between cholesterol, APOE-epsilon4, and the risk of Alzheimer disease (AD) in the Yoruba, a population that has lower cholesterol levels and lower incidence rates of AD compared to African Americans. APOE status needs to be considered when assessing the relationship between lipid levels and AD risk in population studies.
OBJECTIVE: To examine the relationship between cholesterol and other lipids, APOE genotype, and risk of Alzheimer disease (AD) in a population-based study of elderly Yoruba living in Ibadan, Nigeria. METHODS: Blood samples and clinical data were collected from Yoruba study participants aged 70 years and older (N = 1,075) as part of the Indianapolis-Ibadan Dementia Project, a longitudinal epidemiologic study of AD. Cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride levels were measured in fasting blood samples. DNA was extracted and APOE was genotyped. Diagnoses of AD were made by consensus using National Institute of Neurologic Disorders/Stroke-Alzheimer's Disease and Related Disorders Association criteria. RESULTS: Logistic regression models showed interaction after adjusting for age and gender between APOE-epsilon4 genotype and biomarkers in the risk of ADcholesterol*genotype (p = 0.022), LDL*genotype (p= 0.018), and triglyceride*genotype (p = 0.036). Increasing levels of cholesterol and LDL were associated with increased risk of AD in individuals without the APOE-epsilon4 allele, but not in those with APOE-epsilon4. There was no significant association between levels of triglycerides and AD risk in those without APOE-epsilon4. CONCLUSIONS: There was a significant interaction between cholesterol, APOE-epsilon4, and the risk of Alzheimer disease (AD) in the Yoruba, a population that has lower cholesterol levels and lower incidence rates of AD compared to African Americans. APOE status needs to be considered when assessing the relationship between lipid levels and AD risk in population studies.
Authors: T Isbir; B Agaçhan; H Yilmaz; M Aydin; I Kara; E Eker; D Eker Journal: Am J Alzheimers Dis Other Demen Date: 2001 Mar-Apr Impact factor: 2.035
Authors: A Ogunniyi; O Baiyewu; O Gureje; K S Hall; F Unverzagt; S H Siu; S Gao; M Farlow; O S Oluwole; O Komolafe; H C Hendrie Journal: Eur J Neurol Date: 2000-09 Impact factor: 6.089
Authors: T Tokuda; M Calero; E Matsubara; R Vidal; A Kumar; B Permanne; B Zlokovic; J D Smith; M J Ladu; A Rostagno; B Frangione; J Ghiso Journal: Biochem J Date: 2000-06-01 Impact factor: 3.857
Authors: Denis A Evans; David A Bennett; Robert S Wilson; Julia L Bienias; Martha Clare Morris; Paul A Scherr; Liesi E Hebert; Neelum Aggarwal; Laurel A Beckett; Rajiv Joglekar; Elizabeth Berry-Kravis; Julie Schneider Journal: Arch Neurol Date: 2003-02
Authors: H C Hendrie; A Ogunniyi; K S Hall; O Baiyewu; F W Unverzagt; O Gureje; S Gao; R M Evans; A O Ogunseyinde; A O Adeyinka; B Musick; S L Hui Journal: JAMA Date: 2001-02-14 Impact factor: 56.272
Authors: Zaldy Sy Tan; Sudha Seshadri; Alexa Beiser; Peter W F Wilson; Douglas P Kiel; Michael Tocco; Ralph B D'Agostino; Philip A Wolf Journal: Arch Intern Med Date: 2003-05-12
Authors: Hugh C Hendrie; Jill Murrell; Olusegun Baiyewu; Kathleen A Lane; Christianna Purnell; Adesola Ogunniyi; Frederick W Unverzagt; Kathleen Hall; Christopher M Callahan; Andrew J Saykin; Oye Gureje; Ann Hake; Tatiana Foroud; Sujuan Gao Journal: Int Psychogeriatr Date: 2014-02-24 Impact factor: 3.878
Authors: S J Szwast; H C Hendrie; K A Lane; S Gao; S E Taylor; F Unverzagt; J Murrell; M Deeg; A Ogunniyi; M R Farlow; K S Hall Journal: Neurology Date: 2007-11-06 Impact factor: 9.910